26,390 Shares in Bristol Myers Squibb Company $BMY Acquired by Transamerica Financial Advisors LLC

Key Points

• Transamerica Financial Advisors acquired 26,390 shares of Bristol Myers Squibb in the second quarter, valued at approximately $1.52 million. Institutional investors and hedge funds collectively own 76.41% of the company.
• Bristol Myers Squibb reported quarterly adjusted earnings of $2.04 per share and revenue of $12.97 billion, exceeding analyst estimates; revenue increased 5.7% year over year.
• The company pays a quarterly dividend of $0.63 per share, equating to a 3.7% annualized yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $66.06.

Transamerica Financial Advisors LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 26,390 shares of the biopharmaceutical company's stock, valued at approximately $1,521,000.

A number of other hedge funds also recently made changes to their positions in the stock. Life Cycle Investment Partners Ltd bought a new stake in Bristol Myers Squibb in the fourth quarter valued at about $34,406,000. Lazard Asset Management LLC raised its stake in Bristol Myers Squibb by 23.7% during the first quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company's stock valued at $116,693,000 after buying an additional 368,193 shares in the last quarter. Axxcess Wealth Management LLC lifted its holdings in Bristol Myers Squibb by 27.4% during the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company's stock worth $5,322,000 after buying an additional 21,196 shares during the last quarter. Callan Family Office LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $3,575,000. Finally, BlackRock Inc. increased its holdings in shares of Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $67.68 on Thursday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64. The stock's fifty day moving average is $61.25 and its 200-day moving average is $59.60. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The firm has a market capitalization of $138.25 billion, a price-to-earnings ratio of 14.91, a price-to-earnings-growth ratio of 0.18 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the prior year, the company posted $1.46 earnings per share. The company's quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.7%. Bristol Myers Squibb's dividend payout ratio (DPR) is 55.51%.

Wall Street Analysts Forecast Growth

BMY has been the topic of several research analyst reports. Guggenheim restated a "buy" rating and set a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. TD Cowen assumed coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "buy" rating for the company. Piper Sandler started coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued an "overweight" rating on the stock. Truist Financial reaffirmed a "buy" rating and issued a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Finally, Roth Capital began coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a "buy" rating and a $75.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $66.06.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.05% of the stock is currently owned by insiders.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source